TABLE 1.
Association of molecular subtypes and prognostic nutritional index (PNI) in patients with breast cancer.
| Parameters | PNI (N = 785) | PNI (n = 477) | PNI (n = 308) | ||||||||||||
| N | Low PNI (n = 253) | High PNI (n = 532) | χ2 | P value | N | Low PNI (n = 167) | High PNI (n = 310) | χ2 | P value | N | Low PNI (n = 86) | High PNI (n = 222) | χ2 | P value | |
| Core needle biopsy (N = 477) | |||||||||||||||
| Molecular subtypes | 2.454 | 0.653 | |||||||||||||
| Luminal A | 25 (5.24%) | 12 (7.19%) | 13 (4.19%) | ||||||||||||
| Luminal B HER2+ | 67 (14.05%) | 22 (13.17%) | 45 (14.52%) | ||||||||||||
| Luminal B HER2− | 186 (38.99%) | 62 (37.13%) | 124 (40.00%) | ||||||||||||
| HER2 enriched | 91 (19.08%) | 31 (18.56%) | 60 (19.35%) | ||||||||||||
| Triple negative | 108 (22.64%) | 40 (23.95%) | 68 (21.94%) | ||||||||||||
| ER status | 0.049 | 0.825 | |||||||||||||
| Negative | 191 (40.04%) | 68 (40.72%) | 123 (39.68%) | ||||||||||||
| Positive | 286 (59.96%) | 99 (59.28%) | 187 (60.32%) | ||||||||||||
| ER status | 1.179 | 0.758 | |||||||||||||
| 0–25% | 228 (47.80%) | 82 (49.10%) | 146 (47.10%) | ||||||||||||
| 26–50% | 42 (8.80%) | 17 (10.18%) | 25 (8.06%) | ||||||||||||
| 51–75% | 33 (6.92%) | 10 (5.99%) | 23 (7.42%) | ||||||||||||
| 76–100% | 174 (36.48%) | 58 (34.73%) | 116 (37.42%) | ||||||||||||
| PR status | 0.309 | 0.579 | |||||||||||||
| Negative | 189 (39.62%) | 69 (41.32%) | 120 (38.71%) | ||||||||||||
| Positive | 288 (60.38%) | 98 (58.68%) | 190 (61.29%) | ||||||||||||
| PR status | 0.082 | 0.994 | |||||||||||||
| 0–25% | 286 (59.96%) | 100 (59.88%) | 186 (60.00%) | ||||||||||||
| 26–50% | 67 (14.05%) | 24 (14.37%) | 43 (13.87%) | ||||||||||||
| 51–75% | 45 (9.43%) | 15 (8.98%) | 30 (9.68%) | ||||||||||||
| 76–100% | 79 (16.56%) | 28 (16.77%) | 51 (16.45%) | ||||||||||||
| HER2 status | 0.007 | 0.934 | |||||||||||||
| Negative (0– + + ) | 313 (65.62%) | 110 (65.87%) | 203 (65.48%) | ||||||||||||
| Positive ( + + + ) | 164 (34.38%) | 57 (34.13%) | 107 (34.52%) | ||||||||||||
| Ki-67 status | 0.426 | 0.514 | |||||||||||||
| Negative (≤14%) | 84 (17.61%) | 32 (19.16%) | 52 (16.77%) | ||||||||||||
| Positive (>14%) | 393 (82.39%) | 135 (80.84%) | 258 (83.23%) | ||||||||||||
| Ki-67 status | 1.477 | 0.688 | |||||||||||||
| 0–25% | 161 (33.75%) | 55 (32.93%) | 106 (34.19%) | ||||||||||||
| 26–50% | 189 (39.62%) | 66 (39.52%) | 123 (39.68%) | ||||||||||||
| 51–75% | 88 (18.45%) | 29 (17.37%) | 59 (19.03%) | ||||||||||||
| 76–100% | 39 (8.18%) | 17 (10.18%) | 22 (7.10%) | ||||||||||||
| Postoperative pathology (IHC) | |||||||||||||||
| Molecular subtype | 2.118 | 0.714 | 1.093 | 0.895 | 2.149 | 0.708 | |||||||||
| Luminal A | 62 (7.90%) | 17 (6.72%) | 45 (8.46%) | 41 (8.60%) | 13 (7.78%) | 28 (9.02%) | 21 (6.82%) | 4 (4.65%) | 17 (7.66%) | ||||||
| Luminal B HER2+ | 98 (12.48%) | 36 (14.23%) | 62 (11.65%) | 61 (12.79%) | 24 (14.37%) | 37 (11.94%) | 37 (12.01%) | 12 (13.95%) | 25 (11.26%) | ||||||
| Luminal B HER2- | 325 (41.40%) | 105 (41.50%) | 220 (41.35%) | 166 (34.80%) | 58 (34.74%) | 108 (34.84%) | 159 (51.63%) | 47 (54.66%) | 112 (50.45%) | ||||||
| HER2 enriched | 129 (16.44%) | 38 (15.02%) | 91 (17.11%) | 96 (20.12%) | 31 (18.56%) | 65 (20.97%) | 33 (10.71%) | 7 (8.14%) | 26 (11.71%) | ||||||
| Triple negative | 171 (21.78%) | 57 (22.53%) | 114 (21.43%) | 113 (23.69%) | 41 (24.55%) | 72 (23.23%) | 58 (18.83%) | 16 (18.60%) | 42 (18.92%) | ||||||
| ER status | 0.049 | 0.826 | 0.003 | 0.958 | 0.355 | 0.552 | |||||||||
| Negative | 296 (37.71%) | 94 (37.15%) | 202 (37.97%) | 195 (40.88%) | 68 (40.72%) | 127 (40.97%) | 101 (32.79%) | 26 (30.23%) | 75 (33.78%) | ||||||
| Positive | 489 (62.29%) | 159 (62.85%) | 330 (62.03%) | 282 (59.12%) | 99 (59.28%) | 183 (59.03%) | 207 (67.21%) | 60 (69.77%) | 147 (66.22%) | ||||||
| ER status | 3.722 | 0.293 | 0.841 | 0.840 | 5.508 | 0.138 | |||||||||
| 0–25% | 375 (47.77%) | 129 (50.99%) | 246 (46.24%) | 235 (49.27%) | 85 (50.90%) | 150 (48.39%) | 140 (45.46%) | 44 (51.16%) | 96 (43.24%) | ||||||
| 26–50% | 66 (8.41%) | 25 (9.88%) | 41 (7.71%) | 31 (6.50%) | 12 (7.19%) | 19 (6.13%) | 35 (11.36%) | 13 (15.12%) | 22 (9.91%) | ||||||
| 51–75% | 48 (6.11%) | 13 (5.14%) | 35 (6.58%) | 27 (5.66%) | 10 (5.99%) | 17 (5.48%) | 21 (6.82%) | 3 (3.49%) | 18 (8.11%) | ||||||
| 76–100% | 296 (37.71%) | 86 (33.99%) | 210 (39.47%) | 184 (38.57%) | 60 (35.92%) | 124 (40.00%) | 112 (36.36%) | 26 (30.23%) | 86 (38.74%) | ||||||
| PR status | 0.154 | 0.694 | 0.009 | 0.926 | 1.339 | 0.247 | |||||||||
| Negative | 315 (40.13%) | 99 (39.13%) | 216 (40.60%) | 210 (44.03%) | 74 (44.31%) | 136 (43.87%) | 105 (34.09%) | 25 (29.07%) | 80 (36.04%) | ||||||
| Positive | 470 (59.87%) | 154 (60.87%) | 316 (59.40%) | 267 (55.97%) | 93 (55.69%) | 174 (56.13%) | 203 (65.91%) | 61 (70.93%) | 142 (63.96%) | ||||||
| PR status | 0.546 | 0.909 | 0.426 | 0.935 | 1.558 | 0.669 | |||||||||
| 0–25% | 502 (63.95%) | 161 (63.64%) | 341 (64.10%) | 335 (70.23%) | 116 (69.46%) | 219 (70.65%) | 167 (54.22%) | 45 (52.33%) | 122 (54.95%) | ||||||
| 26–50% | 90 (11.46%) | 31 (12.25%) | 59 (11.09%) | 48 (10.06%) | 16 (9.58%) | 32 (10.32%) | 42 (13.64%) | 15 (17.44%) | 27 (12.16%) | ||||||
| 51–75% | 55 (7.01%) | 19 (7.51%) | 36 (6.76%) | 38 (7.97%) | 15 (8.98%) | 23 (7.42%) | 17 (5.52%) | 4 (4.65%) | 13 (5.86%) | ||||||
| 76–100% | 138 (17.58%) | 42 (16.60%) | 96 (18.05%) | 56 (11.74%) | 20 (11.98%) | 36 (11.61%) | 82 (26.62%) | 22 (25.58%) | 60 (27.03%) | ||||||
| HER2 status | 0.065 | 0.799 | 0.045 | 0.833 | 0.062 | 0.804 | |||||||||
| Negative (0– + + ) | 557 (70.96%) | 178 (70.36%) | 379 (71.24%) | 320 (67.09%) | 111 (66.47%) | 209 (67.42%) | 237 (76.95%) | 67 (77.91%) | 170 (76.58%) | ||||||
| Positive ( + + + ) | 228 (29.04%) | 75 (29.64%) | 153 (28.76%) | 157 (32.91%) | 56 (33.53%) | 101 (32.58%) | 71 (23.05%) | 19 (22.09%) | 52 (23.42%) | ||||||
| Ki-67 status | 0.566 | 0.452 | 0.538 | 0.463 | 4.138 | 0.042 | |||||||||
| Negative (≤14%) | 219 (27.90%) | 75 (29.64%) | 144 (27.07%) | 153 (32.08%) | 50 (29.94%) | 103 (33.23%) | 66 (21.43%) | 25 (29.07%) | 41 (18.47%) | ||||||
| Positive (>14%) | 566 (72.10%) | 178 (70.36%) | 388 (72.93%) | 324 (67.92%) | 117 (70.06%) | 207 (66.77%) | 242 (78.57%) | 61 (70.93%) | 181 (81.53%) | ||||||
| Ki-67 status | 2.780 | 0.427 | 2.920 | 0.404 | 0.689 | 0.876 | |||||||||
| 0–25% | 342 (43.57%) | 114 (45.06%) | 228 (42.86%) | 233 (48.84%) | 82 (49.10%) | 151 (48.71%) | 109 (35.39%) | 32 (37.21%) | 77 (34.68%) | ||||||
| 26–50% | 257 (32.74%) | 74 (29.25%) | 183 (34.40%) | 139 (29.14%) | 43 (25.75%) | 96 (30.97%) | 118 (38.31%) | 31 (36.05%) | 87 (39.19%) | ||||||
| 51–75% | 137 (17.45%) | 50 (19.76%) | 87 (16.35%) | 70 (14.68%) | 30 (17.96%) | 40 (12.90%) | 67 (21.75%) | 20 (23.25%) | 47 (21.17%) | ||||||
| 76–100% | 49 (6.24%) | 15 (5.93%) | 34 (6.39%) | 35 (7.34%) | 12 (7.19%) | 23 (7.42%) | 14 (4.55%) | 3 (3.49%) | 11 (4.96%) | ||||||
| AR status | 6.920 | 0.009 | 11.730 | <0.001 | 0.017 | 0.896 | |||||||||
| Negative | 666 (84.84%) | 227 (89.72%) | 439 (82.52%) | 362 (75.89%) | 142 (85.03%) | 220 (70.97%) | 304 (98.70%) | 85 (98.84%) | 219 (98.65%) | ||||||
| Positive | 119 (15.16%) | 26 (10.28%) | 93 (17.48%) | 115 (24.11%) | 25 (14.97%) | 90 (29.03%) | 4 (1.30%) | 1 (1.16%) | 3 (1.35%) | ||||||
| AR status | 6.354 | 0.096 | 10.260 | 0.017 | 0.044 | 0.834 | |||||||||
| 0–25% | 688 (87.65%) | 232 (91.70%) | 456 (85.71%) | 383 (80.29%) | 147 (88.02%) | 236 (76.13%) | 305 (99.03%) | 85 (98.84%) | 220 (99.10%) | ||||||
| 26–50% | 25 (3.18%) | 4 (1.58%) | 21 (3.95%) | 25 (5.24%) | 4 (2.40%) | 21 (6.77%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||||||
| 51–75% | 29 (3.69%) | 6 (2.37%) | 23 (4.32%) | 29 (6.08%) | 6 (3.59%) | 23 (7.42%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||||||
| 76–100% | 43 (5.48%) | 11 (4.35%) | 32 (6.02%) | 40 (8.39%) | 10 (5.99%) | 30 (9.68%) | 3 (0.97%) | 1 (1.16%) | 2 (0.90%) | ||||||
| CK5/6 status | 0.109 | 0.741 | 1.248 | 0.264 | 2.092 | 0.148 | |||||||||
| Negative | 684 (87.13%) | 219 (86.56%) | 465 (87.41%) | 406 (85.12%) | 138 (82.63%) | 268 (86.45%) | 278 (90.26%) | 81 (94.19%) | 197 (88.74%) | ||||||
| Positive | 101 (12.87%) | 34 (13.44%) | 67 (12.59%) | 71 (14.88%) | 29 (17.37%) | 42 (13.55%) | 30 (9.74%) | 5 (5.81%) | 25 (11.26%) | ||||||
| E-cad status | 8.716 | 0.003 | 3.612 | 0.057 | 11.140 | <0.001 | |||||||||
| Negative | 353 (44.97%) | 133 (52.57%) | 220 (41.35%) | 170 (35.64%) | 69 (41.32%) | 101 (32.58%) | 183 (59.42%) | 64 (74.42%) | 119 (53.60%) | ||||||
| Positive | 432 (55.03%) | 120 (47.43%) | 312 (58.65%) | 307 (64.36%) | 98 (58.68%) | 209 (67.42%) | 125 (40.58%) | 22 (25.58%) | 103 (46.40%) | ||||||
| EGFR status | 2.078 | 0.150 | 0.130 | 0.719 | 7.281 | 0.007 | |||||||||
| Negative | 589 (75.03%) | 198 (78.26%) | 391 (73.50%) | 335 (70.23%) | 119 (71.26%) | 216 (69.68%) | 254 (82.47%) | 79 (91.86%) | 175 (78.83%) | ||||||
| Positive | 196 (24.97%) | 55 (21.74%) | 141 (26.50%) | 142 (29.77%) | 48 (28.74%) | 94 (30.32%) | 54 (17.53%) | 7 (8.14%) | 47 (21.17%) | ||||||
| P53 status | 1.381 | 0.240 | 0.137 | 0.712 | 1.994 | 0.158 | |||||||||
| Negative | 395 (50.32%) | 135 (53.36%) | 260 (48.87%) | 243 (50.94%) | 87 (52.10%) | 156 (50.32%) | 152 (49.35%) | 48 (55.81%) | 104 (46.85%) | ||||||
| Positive | 390 (49.68%) | 118 (46.64%) | 272 (51.13%) | 234 (49.06%) | 80 (47.90%) | 154 (49.68%) | 156 (50.65%) | 38 (44.19%) | 118 (53.15%) | ||||||
| P53 status | 1.575 | 0.665 | 4.173 | 0.243 | 0.634 | 0.729 | |||||||||
| 0–25% | 576 (73.38%) | 183 (72.33%) | 393 (73.87%) | 353 (74.00%) | 118 (70.66%) | 235 (75.81%) | 223 (72.41%) | 65 (75.58%) | 158 (71.17%) | ||||||
| 26–50% | 80 (10.19%) | 23 (9.09%) | 57 (10.72%) | 45 (9.44%) | 14 (8.38%) | 31 (10.00%) | 35 (11.36%) | 9 (10.47%) | 26 (11.71%) | ||||||
| 51–75% | 108 (13.75%) | 39 (15.42%) | 69 (12.97%) | 58 (12.16%) | 27 (16.17%) | 31 (10.00%) | 50 (16.23%) | 12 (13.95%) | 38 (17.12%) | ||||||
| 76–100% | 21 (2.68%) | 8 (3.16%) | 13 (2.44%) | 21 (4.40%) | 8 (4.79%) | 13 (4.19%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | ||||||
| TOP2A status | 4.598 | 0.032 | 0.024 | 0.877 | 15.940 | <0.0001 | |||||||||
| Negative | 299 (38.09%) | 110 (43.48%) | 189 (35.53%) | 165 (34.59%) | 57 (34.13%) | 108 (34.84%) | 134 (43.51%) | 53 (61.63%) | 81 (36.49%) | ||||||
| Positive | 486 (61.91%) | 143 (56.52%) | 343 (64.47%) | 312 (65.41%) | 110 (65.87%) | 202 (65.16%) | 174 (56.49%) | 33 (38.37%) | 141 (63.51%) | ||||||
| TOP2A status | 0.408 | 0.939 | 1.974 | 0.578 | 3.368 | 0.338 | |||||||||
| 0–25% | 575 (73.25%) | 187 (73.91%) | 388 (72.92%) | 354 (74.21%) | 120 (71.86%) | 234 (75.48%) | 221 (71.76%) | 67 (77.90%) | 154 (69.37%) | ||||||
| 26–50% | 158 (20.13%) | 48 (18.97%) | 110 (20.68%) | 88 (18.45%) | 31 (18.56%) | 57 (18.39%) | 70 (22.73%) | 17 (19.77%) | 53 (23.87%) | ||||||
| 51–75% | 49 (6.24%) | 17 (6.72%) | 32 (6.02%) | 33 (6.92%) | 15 (8.98%) | 18 (5.81%) | 16 (5.19%) | 2 (2.33%) | 14 (6.31%) | ||||||
| 76–100% | 3 (0.38%) | 1 (0.40%) | 2 (0.38%) | 2 (0.42%) | 1 (0.60%) | 1 (0.32%) | 1 (0.32%) | 0 (0.00%) | 1 (0.45%) | ||||||
| Lymph vessel invasion | 0.756 | 0.385 | 0.001 | 0.995 | 3.936 | 0.047 | |||||||||
| Negative | 558 (71.08%) | 185 (73.12%) | 373 (70.11%) | 320 (67.09%) | 112 (67.07%) | 208 (67.10%) | 238 (77.27%) | 73 (84.88%) | 165 (74.32%) | ||||||
| Positive | 227 (28.92%) | 68 (26.88%) | 159 (29.89%) | 157 (32.91%) | 55 (32.93%) | 102 (32.90%) | 70 (22.73%) | 13 (15.12%) | 57 (25.68%) | ||||||
| Neural invasion | 0.041 | 0.840 | 0.018 | 0.892 | 0.005 | 0.944 | |||||||||
| Negative | 670 (85.35%) | 215 (84.98%) | 455 (85.53%) | 384 (80.50%) | 135 (80.84%) | 249 (80.32%) | 286 (92.86%) | 80 (93.02%) | 206 (92.79%) | ||||||
| Positive | 115 (14.65%) | 38 (15.02%) | 77 (14.47%) | 93 (19.50%) | 32 (19.16%) | 61 (19.68%) | 22 (7.14%) | 6 (6.98%) | 16 (7.21%) | ||||||
ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; EFGR, epidermal growth factor receptor; IHC, immunohistochemistry.